Skip to main content

Advertisement

SpringerLink
Log in

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. In our study, we analyzed these genetic alterations in 394 thyroid tissue samples (197 papillary carcinomas and 197 healthy). The somatic mutations and translocations were detected by Light Cycler melting method and Real-Time Polymerase Chain Reaction techniques, respectively. In tumorous samples, 86 BRAF (44.2 %), 5 NRAS (3.1 %), 2 HRAS (1.0 %) and 1 KRAS (0.5 %) mutations were found, as well as 9 RET/PTC1 (4.6 %) and 1 RET/PTC3 (0.5 %) translocations. No genetic alteration was seen in the non tumorous control thyroid tissues. No correlation was detected between the genetic variants and the pathological subtypes of papillary cancer as well as the severity of the disease. Our results are only partly concordant with the data found in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

BRAF :

v-raf murine sarcoma viral oncogene homolog B1

EGFR:

Epidermal growth factor receptor

FNA:

Fine needle aspiration

FNAB:

Fine needle aspiration biopsy

FVPTC:

Follicular variant papillary carcinoma

HRAS :

v-Ha-ras Harvey rat sarcoma viral oncogene homolog

KRAS :

v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

MAPK:

Mitogen-activated protein kinase

PAX8/PPAR-gamma:

Paired box8/peroxisome proliferator-activated receptor gamma

PTC:

Papillary thyroid carcinoma

PTMC:

Papillary thyroid microcarcinoma

RAS:

Rat sarcoma viral oncogene homolog

RET/PTC :

RET tyrosine-kinase proto-oncogene/papillary thyroid carcinoma

References

  1. Benvenga S (2008) Update on thyroid cancer. Horm Metab Res 40(5):323–328. doi:10.1055/s-2008-1073155

    Article  CAS  PubMed  Google Scholar 

  2. Elisei R (2014) Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it? J Clin Endocrinol Metab 99(2):412–414. doi:10.1210/jc.2014-1130

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Lakatos P, Takacs I (2007) Pajzsmirigybetegsegek: a gyakorlat oldalarol. Budapest

  4. Woodruff SL, Arowolo OA, Akute OO, Afolabi AO, Nwariaku F (2010) Global variation in the pattern of differentiated thyroid cancer. Am J Surg 200(4):462–466. doi:10.1016/j.amjsurg.2010.03.009

    Article  PubMed  Google Scholar 

  5. Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR (1991) High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 51(10):2690–2693

    CAS  PubMed  Google Scholar 

  6. Vanderpump MP, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K, Franklyn JA (2011) Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 377(9782):2007–2012. doi:10.1016/S0140-6736(11)60693-4

    Article  CAS  PubMed  Google Scholar 

  7. Szybinski Z (2009) Iodine prophylaxis in Poland in light of the WHO recommendation on reduction of the daily salt intake. Pediatr Endocrinol Diabetes Metab 15(2):103–107

    PubMed  Google Scholar 

  8. Moreno-Reyes R, Van Oyen H, Vandevijvere S (2011) Optimization of iodine intake in Belgium. Ann Endocrinol (Paris) 72(2):158–161. doi:10.1016/j.ando.2011.03.021

    Article  CAS  Google Scholar 

  9. Schlumberger M (2007) Papillary and follicular thyroid carcinoma. Ann Endocrinol (Paris) 68(2–3):120–128. doi:10.1016/j.ando.2007.04.004

    Article  CAS  Google Scholar 

  10. Cheng SP, Liu CL, Tzen CY, Yang TL, Jeng KS, Liu TP, Lee JJ (2008) Characteristics of well-differentiated thyroid cancer associated with multinodular goiter. Langenbeck's Arch Surg 393(5):729–732. doi:10.1007/s00423-008-0327-1

    Article  Google Scholar 

  11. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569–580. doi:10.1038/nrendo.2011.142

    Article  CAS  PubMed  Google Scholar 

  12. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94(6):2092–2098. doi:10.1210/jc.2009-0247

    Article  CAS  PubMed  Google Scholar 

  13. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216–222

    Article  PubMed  Google Scholar 

  14. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63(7):1454–1457

    CAS  PubMed  Google Scholar 

  15. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28(7):742–762. doi:10.1210/er.2007-0007

    Article  CAS  PubMed  Google Scholar 

  16. Paulson L, Shindo M, Schuff K, Corless C (2012) The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 138(1):44–49. doi:10.1001/archoto.2011.226

    Article  PubMed  Google Scholar 

  17. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95(9):4197–4205. doi:10.1210/jc.2010-0337

    Article  CAS  PubMed  Google Scholar 

  18. Lee JH, Lee ES, Kim YS (2007) Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110(1):38–46. doi:10.1002/cncr.22754

    Article  PubMed  Google Scholar 

  19. Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC (2011) Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 21(7):717–723. doi:10.1089/thy.2011.0021

    Article  CAS  PubMed  Google Scholar 

  20. Guerra A, Zeppa P, Bifulco M, Vitale M (2014) Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Thyroid 24(2):254–259. doi:10.1089/thy.2013.0235

    Article  CAS  PubMed  Google Scholar 

  21. Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G (2013) BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathology 121(6):291–297. doi:10.1002/cncy.21258

    Article  CAS  PubMed  Google Scholar 

  22. Bellevicine C, Cozzolino I, Malapelle U, Zeppa P, Troncone G (2012) Cytological and molecular features of papillary thyroid carcinoma with prominent hobnail features: a case report. Acta Cytol 56(5):560–564. doi:10.1159/000338395

    Article  PubMed  Google Scholar 

  23. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.1200/JCO.2008.20.1426

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M (2009) Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94(5):1612–1617. doi:10.1210/jc.2008-2390

    Article  CAS  PubMed  Google Scholar 

  25. Gandhi M, Evdokimova V, Nikiforov YE (2010) Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol 321(1):36–43. doi:10.1016/j.mce.2009.09.013

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Soares P, Celestino R, Gaspar da Rocha A, Sobrinho-Simoes M (2014) Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? Int J Surg Pathol 22(2):113–119. doi:10.1177/1066896913517394

    Article  PubMed  Google Scholar 

  27. Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML (2013) Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis. Thyroid 23(12):1525–1531. doi:10.1089/thy.2013.0154

    Article  CAS  PubMed  Google Scholar 

  28. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M (2013) Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 20(7):2266–2273. doi:10.1245/s10434-012-2851-z

    Article  PubMed  Google Scholar 

  29. Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y (2014) Concomitant RAS, RET/PTC, or BRAF Mutations in Advanced Stage of Papillary Thyroid Carcinoma. Thyroid 24(8):1256–1266. doi:10.1089/thy.2013.0610

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D, De Micco C (2006) Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 37(7):824–830. doi:10.1016/j.humpath.2006.01.030

    Article  PubMed  Google Scholar 

  31. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13(1):3–16

    Article  CAS  PubMed  Google Scholar 

  32. Szántó Z, Zoltán KI (2008) A pajzsmirigy cancerogenesisében szereplő oncogének, antioncogének és egyéb tumormarkerek diagnosztikai és prognosztikai jelentősége. Orvostudományi Értesítő 81(1):9–12

    Google Scholar 

  33. Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8(1):83–95. doi:10.1586/14737159.8.1.83

    Article  CAS  PubMed  Google Scholar 

  34. Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S (2011) Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J 58(5):381–393

    Article  CAS  PubMed  Google Scholar 

  35. Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, Mabuchi K, Tronko MD, Nikiforov YE (2013) RET/PTC and PAX8/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 119(10):1792–1799. doi:10.1002/cncr.27893

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, Hodak SP, Nikiforova MN, Carty SE, Nikiforov YE (2014) PAX8/PPARgamma Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. Thyroid. doi:10.1089/thy.2014.0067

    PubMed Central  PubMed  Google Scholar 

  37. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M (2006) PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91(1):213–220. doi:10.1210/jcem.91.1.9999

    Article  CAS  PubMed  Google Scholar 

  38. Klemke M, Drieschner N, Belge G, Burchardt K, Junker K, Bullerdiek J (2012) Detection of PAX8-PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RT-PCR. Genes Chromosom Cancer 51(4):402–408. doi:10.1002/gcc.21925

    Article  CAS  PubMed  Google Scholar 

  39. Eszlinger M, Krogdahl A, Munz S, Rehfeld C, Precht Jensen EM, Ferraz C, Bosenberg E, Drieschner N, Scholz M, Hegedus L, Paschke R (2014) Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid 24(2):305–313. doi:10.1089/thy.2013.0278

    Article  CAS  PubMed  Google Scholar 

  40. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404. doi:10.1210/jc.2003-030838

    Article  CAS  PubMed  Google Scholar 

  41. Gandolfi G, Sancisi V, Torricelli F, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A (2013) Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab 98(5):E934–E942. doi:10.1210/jc.2012-3930

    Article  PubMed  Google Scholar 

  42. Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381(9871):1058–1069. doi:10.1016/S0140-6736(13)60109-9

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M (2012) A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97(7):2333–2340. doi:10.1210/jc.2011-3106

    Article  CAS  PubMed  Google Scholar 

  44. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R (2006) Correlation between B-RAF(V600E) mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13(2):455–464

    Article  CAS  PubMed  Google Scholar 

  45. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M (2005) Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv Int J Pathol 446(6):589–595. doi:10.1007/s00428-005-1236-0

    Article  CAS  Google Scholar 

  46. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13(2):455–464. doi:10.1677/erc.1.01086

    Article  CAS  PubMed  Google Scholar 

  47. Eszlinger M, Niedziela M, Typlt E, Jaeschke H, Huth S, Schaarschmidt J, Aigner T, Trejster E, Krohn K, Bosenberg E, Paschke R (2014) Somatic mutations in 33 benign and malignant hot thyroid nodules in children and adolescents. Mol Cell Endocrinol 393(1–2):39–45. doi:10.1016/j.mce.2014.05.023

    Article  CAS  PubMed  Google Scholar 

  48. Czarniecka A, Rusinek D, Stobiecka E, Krajewska J, Kowal M, Kropinska A, Zebracka J, Kowalska M, Wloch J, Maciejewski A, Handkiewicz-Junak D (2010) Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. Endokrynol Pol 61(5):462–466

    PubMed  Google Scholar 

  49. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M (2008) BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28(1A):305–308

    PubMed  Google Scholar 

  50. Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP (2014) BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 124(9):E389–E393. doi:10.1002/lary.24668

    Article  CAS  PubMed  Google Scholar 

  51. Boric M, Stanicic J, Dabelic N, Jukic T, Kusic Z (2009) Iodine supplementation in pregnancy. Acta clinica Croatica 48(4):469–473

    PubMed  Google Scholar 

  52. Goretzki PE, Witte J, Dotzenrath C, Schulte KM, Simon D, Roher HD (1998) Geographical differences of thyroid carcinoma and basic molecular principles. Langenbecks Arch Chir Suppl Kongressbd 115:200–202

    CAS  PubMed  Google Scholar 

  53. Fleury Y, van Melle G, Woringer V, Temler E, Gaillard RC, Portmann L (1999) Iodine nutrition and prevalence of goiter in adolescents in the Canton of Vaud. Schweiz Med Wochenschr 129(47):1831–1838

    CAS  PubMed  Google Scholar 

  54. Lind P, Kumnig G, Heinisch M, Igerc I, Mikosch P, Gallowitsch HJ, Kresnik E, Gomez I, Unterweger O, Aigner H (2002) Iodine supplementation in Austria: methods and results. Thyroid 12(10):903–907. doi:10.1089/105072502761016539

    Article  CAS  PubMed  Google Scholar 

  55. Guo HQ, Zhao H, Zhang ZH, Zhu YL, Xiao T, Pan QJ (2014) Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China. Dis Markers 2014:912182. doi:10.1155/2014/912182

    PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported in part by the Hungarian Health Research Council (ETT-10-151/2009) as well as Osseus Foundation. We also thank Violetta Kalocsáné Piurkó for the preparation of paraffin-embedded samples.

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, Semmelweis University, Korányi S. Str. 2a, Budapest, 1083, Hungary

    Bálint Tobiás, Csaba Halászlaki, Bernadett Balla, János P. Kósa, Péter Horváth, István Takács, Zsolt Nagy, Evelin Horváth, Zsuzsanna Putz, Magdolna Dank & Péter Lakatos

  2. 1st Department of Surgery, Semmelweis University, Budapest, Hungary

    János Horányi

  3. 2nd Department of Pathology, Semmelweis University, Budapest, Hungary

    Balázs Járay, Eszter Székely & Tamás Székely

  4. Department of Radiology and Oncotherapy, Semmelweis University, Budapest, Hungary

    Gabriella Győri

  5. PentaCore Laboratory, Budapest, Hungary

    János P. Kósa & Kristóf Árvai

  6. Department of Medicine, University of Szeged, Szeged, Hungary

    Zsuzsanna Valkusz

  7. Department of Pathology, University of Szeged, Szeged, Hungary

    Béla Vasas & Béla Iványi

Authors
  1. Bálint Tobiás
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Csaba Halászlaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernadett Balla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. János P. Kósa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kristóf Árvai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Péter Horváth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. István Takács
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zsolt Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Evelin Horváth
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. János Horányi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Balázs Járay
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Eszter Székely
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tamás Székely
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Gabriella Győri
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Zsuzsanna Putz
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Magdolna Dank
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Zsuzsanna Valkusz
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Béla Vasas
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Béla Iványi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Péter Lakatos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bálint Tobiás.

Additional information

Bálint Tobiás and Csaba Halászlaki equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tobiás, B., Halászlaki, C., Balla, B. et al. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Pathol. Oncol. Res. 22, 27–33 (2016). https://doi.org/10.1007/s12253-015-9969-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-015-9969-9

Keywords

Search

Navigation